GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
NASDAQ:STDY
Delisted

SteadyMed Ltd. Fund Forecast

$4.73
+0 (+0%)
At Close: Sep 18, 2018
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

SteadyMed Ltd. fund upgraded to Buy Candidate.
(Updated on Sep 18, 2018)

Buy or Hold candidate since Aug 24, 2018 PDF

No changes to the price of SteadyMed Ltd. fund on the last trading day (Tuesday, 18th Sep 2018). During the last trading day the fund fluctuated 0% from a day low at $4.73 to a day high of $4.73. The price has been going up and down for this period, and there has been a 0% change for the last 2 weeks.

The fund lies in the middle of a narrow and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the fund is expected to rise 5.09% during the next 3 months and, with a 90% probability hold a price between $4.91 and $5.14 at the end of this 3-month period.

Check out how to make money doing surveys! Ad

STDY Signals & Forecast

The SteadyMed Ltd. fund holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $4.73 and $4.72. A breakdown below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Tuesday, August 28, 2018, and so far it has fallen -0.526%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for SteadyMed Ltd. fund

SteadyMed Ltd. finds support from accumulated volume at $4.65 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the fund tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the fund During the last day, the fund moved $0 between high and low, or 0%. For the last week the fund has had daily average volatility of 0%

Our recommended stop-loss: $4.53 (-4.06%) (This fund has low daily movements and this gives low risk. There is a sell signal from a pivot top found 14 days ago.)

Trading Expectations (STDY) For The Upcoming Trading Day Of Wednesday 19th

For the upcoming trading day on Wednesday, 19th we expect SteadyMed Ltd. to open at $4.73, and during the day (based on 14 day Average True Range), to move between $4.69 and $4.76, which gives a possible trading interval of +/-$0.0323 (+/-0.68%) up or down from last closing price. If SteadyMed Ltd. takes out the full calculated possible swing range there will be an estimated 1.37% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $4.75 (0.53%) than the support at $4.65 (1.59%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is SteadyMed Ltd. fund A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for SteadyMed Ltd. fund to perform well in the short-term. We have upgraded our analysis conclusion for this fund since the last evaluation from a Hold/Accumulate to a Buy candidate.

Current score: 1.260 Buy Candidate Upgraded

Predicted Opening Price for SteadyMed Ltd. of Wednesday, September 19, 2018

Fair opening price September 19, 2018 Current price
$4.73 ( 0%) $4.73

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for STDY

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.73 .
R2 4.73 .
R1 4.73 .
Current price: 4.73
Support S1 4.73 .
S2 4.73 .
S3 4.73 .

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0 .
R2 4.78 1.06 %
R1 4.75 0.529 %
Current price 4.73
Support S1 4.65 -1.59%
S2 4.60 -2.65%
S3 4.50 -4.76%

FAQ

What is the symbol for SteadyMed Ltd. Fund and on which exchange is it traded?
The symbol for SteadyMed Ltd. is STDY and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell SteadyMed Ltd. Fund?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for SteadyMed Ltd. fund to perform well in the short-term. We have upgraded our analysis conclusion for this fund since the last evaluation from a Hold/Accumulate to a Buy candidate.

How to buy SteadyMed Ltd. Fund?
SteadyMed Ltd. Fund can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy SteadyMed Ltd. Fund.

What's the current price of SteadyMed Ltd. Fund?
As of the end of day on the 2018-09-18, the price of an SteadyMed Ltd. (STDY) share was $4.73.

What is the 52-week high and low for SteadyMed Ltd. Fund?
The 52-week high for SteadyMed Ltd. Fund is $4.80 and the 52-week low is $2.60.
Click to get the best stock tips daily for free!

About SteadyMed Ltd.

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and other diseases with unmet parenteral delivery needs. It engages in developing Trevyent for the treatment of pulmonary arterial hypertension. The company also develops two products for the treatment of post-surgical and acute pain in the home ... STDY Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT